Skip to content

Net Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.68B+8.8%
CTO
Citius Oncology, Inc.CTOR
-$26.61M-244%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-$33.44M+22.8%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
-$13.69M-190%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$632.8M-388%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$19.63M-49.3%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s net income?
TuHURA Biosciences, Inc. (HURA) reported net income of -$7.54M in Q1 2026.
How has TuHURA Biosciences, Inc.'s net income changed year-over-year?
TuHURA Biosciences, Inc.'s net income decreased by 13.1% year-over-year, from -$6.66M to -$7.54M.
What is the long-term trend for TuHURA Biosciences, Inc.'s net income?
Over 3 years (2022 to 2025), TuHURA Biosciences, Inc.'s net income has grown at a 9.9% compound annual growth rate (CAGR), from -$22.66M to -$30.05M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.